GO
Loading...

TD Ameritrade Under Pressure From Hedge Funds to Merge

CNBC.com
Wednesday, 6 Jun 2007 | 7:36 AM ET

Two hedge funds took an 8.4% stake in TD Ameritrade Holding and sent the online brokerage a letter urging it to merge with one of its competitors, according to a regulatory filing made Tuesday.

"Based on our due diligence, we believe that TD Ameritrade can dramatically increase long-term shareholder value through a combination with E*Trade Financial ("E*Trade") or Charles Schwab ("Schwab")," said the letter from SAC Capital and Jana Partners.

  Price   Change %Change
BGES
---
ETFC
---
SCHW
---

TD Ameritrade expressed willingness to consider such an offer. "We look at M&A every day," TD Ameritrade spokeswoman Katrina Becker told CNBC. "We believe there will be more consolidation in the industry. But it has to be the right deal and good for shareholders."

TD Ameritrade CEO
Hedge funds are pushing the company to merge, with Joe Moglia, TD Ameritrade Holding Corp. CEO and CNBC's Joe Kernen

The hedge funds added that they believe representatives of Toronto-Dominion Bank on TD Ameritrade's board may be thwarting such a merger because the bank "views its significant ownership and influence on (TD Ameritrade) as being critical to its U.S. strategy."

TD Ameritrade noted in the filing that its board has formed a mergers and acquisitions committee that includes three outside independent directors.

After closing at $19.95 during regular market hours Tuesday, TD Ameritrade shares rose more than 6% in post-market trade.

  Price   Change %Change
ETFC
---
AMTD
---

Featured

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Many analysts still believe Twitter is overvalued after the stock's surge on its purchase of social data firm Gnip. CNBC's Morgan Brennan reports.

  • Rounding up all the earnings news investors should be keeping an eye on, including Goldman Sachs and Morgan Stanley preparing to report Q1 data on Thursday, with CNBC's Melissa Lee, Kate Kelly and Dominic Chu.

  • Sam Isaly, OrbiMed Advisors, shares his positive outlook for Regeneron, and what he thinks about Amgen's pipeline.